{"id":446542,"title":"Notice: Multiple additions to the Prescription Drug List (PDL) [2022-10-14] - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-03","captureTimestamp":"2026-01-03T12:11:47.143000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2022-10-14.html?wbdisable=false","snippet":"Notice: Multiple additions to the Prescription Drug List (PDL) October 14, 2022 Our file number: 22-110895-558 The purpose of this Notice of Amendment is to notify about the addition of abrocitinib, asciminb, belzutifan, difelikefalin, maribavir and tezepelumab to the…","rawSnapshotUrl":"/api/snapshots/raw/446542","browseUrl":"https://replay.healtharchive.ca/job-6/20260103121147/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2022-10-14.html?wbdisable=false#ha_snapshot=446542","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}